LAVA Therapeutics NV is a pioneering biotechnology company based in Utrecht, the Netherlands, dedicated to transforming cancer treatment through its proprietary gamma-delta bispecific T-cell activators (gamma-delta bsTCE). The firm's comprehensive development pipeline is aimed at creating novel therapies that specifically target both solid tumors and hematologic malignancies, showcasing its commitment to optimizing immune responses against cancer. With an innovative technological platform and a strategic emphasis on oncology, LAVA Therapeutics is strategically positioned to lead significant advancements in cancer care, ultimately striving to enhance patient outcomes in a rapidly evolving healthcare environment. Show more

Location: YALELAAN 62, UTRECHT, NETHERLANDS, 3584 CM, Utrecht, 3584 CM, USA | Website: https://www.lavatherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

45.77M

52 Wk Range

$0.85 - $1.82

Previous Close

$1.74

Open

$1.74

Volume

N/A

Day Range

$1.74 - $1.74

Enterprise Value

-3.893M

Cash

49.66M

Avg Qtr Burn

-4.868M

Insider Ownership

16.39%

Institutional Own.

27.54%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PF-08046052 (formerly LAVA-1223) Details Cancer, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LAVA-1266 Details Cancer, Hematologic malignancies, Acute myeloid leukemia, Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LAVA-1207 Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer, Prostate disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LAVA-051 ( gamma-delta bsTCE targeting CD1d-expressing tumors) Details Solid tumor/s, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Multiple myeloma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.